ABSTRACT
The efficacy and safety of fluvastatin, a new 3-hydroxy 3-methyl-glutaryl coenzyme -A reductase inhibitor, was studied in ten nephrotic patients with hypercholesterolemia [fasting total cholesterol over 240 mg/dl and LDL-cholesterol over 160 mg/dl]. Forty mg of fluvastatin daily, for twelve weeks, decreased total cholesterol from 386 +/- 123 mg/dl to 294 +/- 78 mg/dl [p<0.01] and LDL-cholesterol from 233 +/- 88 mg/dl to 171 +/- 64 mg/dl [p<0.01]. HDL-cholesterol was slightly increased. Triglyceride level decreased 33%, from 517 +/- 413 mg/dl to 393 +/- 190 mg/dl. VLDL-cholesterol also decreased significantly from 102 +/- 64 mg/dl to 65 +/- 30 mg/dl [p<0.05]. No adverse effect was seen. We conclude that fluvastatin has a favorable effect on serum lipoproteins in nephrotic patients